Purdue Pharma’s Strong Track Record of
Helping Address Prescription Drug Abuse and Diversion

The opioid crisis is among our nation’s top health challenges. Purdue has long been an industry leader in the fight against opioid abuse and diversion, and has dedicated significant resources to developing opioids with abuse-deterrent properties. 


Our series of initiatives address many important dimensions of this complex problem.  As a company, we have taken a number of significant steps including:

  • Investing in research to develop non-opioid pain medications.
  • Delivering the US Surgeon General’s TurnTheTideRx materials, which review considerations when prescribing opioids for chronic pain, to healthcare professionals.
  • Sharing the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain with thousands of prescribers and pharmacists.
  • Supporting the National Sheriffs’ Association (NSA) with a grant to provide front-line officers with the rescue drug naloxone.
  • Working with the National Institutes of Health (NIH) as part of President Trump’s Opioid Commission on a public-private partnership focused on the development of non-addictive pain medications, innovative addition deterrent formulas and treatments for overdose.
  • Becoming a member of the Prescription Drug Safety Network and supporting efforts to bring prevention education created by EVERFI, the leading prevention education innovator, to high school students across the US.
  • Collaborating with the US Conference of Mayors (USCM) to provide awards to cities for the “Safeguard My Meds Prescription Drug Abuse Prevention Recognition Program” to honor outstanding initiatives that address prescription drug misuse and abuse in America’s cities.


We continue to lead our industry in developing this technology. Purdue has developed three of the ten Food and Drug Administration (FDA)-approved opioids with abuse-deterrent properties.

  • The Drug Enforcement Agency (DEA), FDA, National Institute on Drug Abuse (NIDA), and other agencies have stated that opioids with abuse-deterrent properties are making an impact but must be part of a comprehensive national strategy to address the opioid crisis that also includes prevention and treatment.
  • Approximately 90% of opioid analgesics are generic, immediate-release, and non-abuse-deterrent.1


Purdue provides law enforcement training, education, and materials to help address prescription drug abuse and diversion.

  • Our RxREACTS program provides training on abuse detection and deterrence to physicians, pharmacists, and allied healthcare professionals, and our Law Enforcement Liaison & Education (LELE) department provides similar training to law enforcement at the state and local levels.  
  • We support the National Sheriffs’ Association (NSA) with funding for training and distribution of naloxone kits. To date, we’ve provided the NSA with $850,000 which has supported the distribution of 500 naloxone kits to 12 local law enforcement agencies in eight states. The program has also enabled the NSA to reach more than 600 deputies and officers through onsite training at nine law enforcement agencies in Ohio, Florida, North Carolina, South Carolina, Virginia and Kentucky.
  • RxPATROL® (Pattern Analysis Tracking Robberies and Other Losses) is the first and only national database that tracks, analyzes, and provides information on pharmacy crime to law enforcement and retail pharmacies. Created by Purdue in May 2003, RxPATROL®  now has more than 13,600 registered users and helps law enforcement solve pharmacy crimes, and educates pharmacy owners on how they can protect themselves, their businesses, and their customers.
  • We sponsor the National Association of Drug Diversion Investigators (NADDI) Law Enforcement Grant program, which provides additional resources to law enforcement to help combat prescription drug abuse and diversion.
  • Purdue teamed with the Connecticut-based The Governor’s Prevention Partnership in 2017 to launch a series of radio PSAs to raise awareness about the opioid crisis. The initiative consists of spots on iHeartRadio stations in Connecticut. The PSA initiative marks the latest effort in a 20-year relationship between Purdue and The Governor’s Prevention Partnership, a public-private agency focused on education about youth issues, including substance abuse. 
  • We support the Partnership for Drug Free Kids’ Medicine Abuse Project that includes a toll-free hotline (Spanish and English) for parents to receive advice, guidance, and resources to help support their children who may be addicted to prescription drugs.


Purdue was the first pharmaceutical company to advocate for the use of Prescription Drug Monitoring Programs (PDMPs) in states across the country.

  • We provided a $3.1 million grant to help form a public-private partnership with the Commonwealth of Virginia to enhance its PDMP and help integrate the use of its data into the regular workflow of doctors and nurses. The grant allows the Virginia Department of Health Professions to connect the state PDMP with electronic health records used by doctors and pharmacies.
  • In 2017, we announced a partnership with Project Lazarus and Safe Kids North Carolina to support state-wide medicine disposal activities and conduct systematic research to evaluate the impact of community-based prevention programs on opioid-related overdoses, abuse, and diversion.
  • We provided a $1 million grant to the National Association of Boards of Pharmacy (NABP) with a grant to establish PMP InterConnect, a system to help states share prescription data to help deter doctor-shopping across state lines, now used in more than 40 states.
  • We developed the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System to measure rates of abuse, misuse, and diversion across the nation. RADARS® now operates as an independent, nonprofit operation of the Rocky Mountain Poison and Drug Center (RMPDC), a division of the Denver Health and Hospital Authority (DHHA). It contributes to the understanding of trends, aids in the development of effective interventions, and assists pharmaceutical companies in fulfillment of their regulatory obligations, such as risk evaluation and mitigation strategies (REMS). 


 1 IQVIA NPA data through August 2017